Page 70 - Genentech News Today

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 5, 2023--

/PRNewswire/ -- Kythera Labs, a leading healthcare technology and data analytics company, announces the appointment of Glynn Dennis, Jr., Ph.D., as its new...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to ...

– Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting –– PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumor growth, disease progression, and treatment...

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.

(RTTNews) - The Switzerland market ended marginally up on Tuesday after swinging between gains and losses, after a somewhat lackluster session. T...

Mild cognitive impairment is underdiagnosed, with only 0.1% of clinicians and practices with diagnosis rates within the expected range.

The Switzerland market ended marginally up on Tuesday after swinging between gains and losses, after a somewhat lackluster session..

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the closing...

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.